Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
US pharmacy KPH Healthcare Services, acting on behalf of purchasing giant McKesson, has seen an antitrust suit filed against Viatris’ Mylan and Pfizer dismissed, although the court said it would allow plaintiffs to come back with a further complaint.
A US district court has denied Zydus Cadila’s motion for summary judgment on Sherman Act antitrust counterclaims against Takeda over a branded formulation of lansoprazole, finding that the originator did have basis to sue the ANDA sponsor again in 2018.
Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.
Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.
Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.